PLYMOUTH
MEETING, Pa., March 12,
2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a
biotechnology company focused on developing and commercializing DNA
medicines to help treat and protect people from HPV-associated
diseases, cancers, and infectious diseases, today announced that
fourth quarter and year-end 2024 financial results will be released
after the market close on March 18,
2025. Following the release, INOVIO will host a live
conference call and webcast at 4:30 p.m.
ET to discuss financial results and provide a general
business update.
The live webcast will be available online at
http://ir.inovio.com/events-and-presentations/default.aspx. This is
a listen-only event but will include a live Q&A with analysts.
The webcast will be archived and available for replay for 90 days
following the event.
About INOVIO
INOVIO is a biotechnology company
focused on developing and commercializing DNA medicines to help
treat and protect people from HPV-related diseases,
cancers, and infectious diseases. INOVIO's technology
optimizes the design and delivery of innovative DNA medicines that
teach the body to manufacture its own disease-fighting tools. For
more information, visit www.inovio.com.
Contacts
Media: Jennie Willson,
(267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare,
(443) 213-0505, investor.relations@inovio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inovio-to-report-fourth-quarter-and-year-end-2024-financial-results-on-march-18-2025-302400150.html
SOURCE INOVIO Pharmaceuticals, Inc.
